Q9UHD8 (SEPT9_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 29, 2013.
Version 119.
History...
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Web links·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Septin-9 Alternative name(s): MLL septin-like fusion protein MSF-A Short name=MLL septin-like fusion protein Ovarian/Breast septin Short name=Ov/Br septin Septin D1 | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) [Reference proteome] | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 586 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Filament-forming cytoskeletal GTPase By similarity. May play a role in cytokinesis Potential. May play a role in the internalization of 2 intracellular microbial pathogens, Listeria monocytogenes and Shigella flexneri. |
| Subunit structure | Septins polymerize into heterooligomeric protein complexes that form filaments, and associate with cellular membranes, actin filaments, and microtubules. GTPase activity is required for filament formation. Interacts with SEPT2, SEPT6, SEPT7, SEPT11 and SEPT14. Interacts with RTKN and ARHGEF18. In a mesenchymal cell line, Rho/RTKN signals cause disruption of wild-type septin filaments, but not of those containing isoform 2 variants HNA Trp-106 and Phe-111. In a mesenchymal cell line, isoform 2 variants HNA Trp-106 and Phe-111, but not wild type, form filaments with SEPT4. Ref.12 Ref.14 Ref.15 Ref.18 Ref.19 Ref.22 |
| Subcellular location | Cytoplasm › cytoskeleton. Note: In an epithelial cell line, concentrates at cell-cell contact areas. After TGF-beta1 treatment and induction of epithelial to mesenchymal transition, colocalizes partly with actin stress fibers. During bacterial infection, displays a collar shape structure next to actin at the pole of invading bacteria. Ref.18 Ref.19 |
| Tissue specificity | Widely expressed. Isoforms are differentially expressed in testes, kidney, liver heart, spleen, brain, peripheral blood leukocytes, skeletal muscle and kidney. Specific isoforms appear to demonstrate tissue specificity. Isoform 5 is the most highly expressed in fetal tissue. Isoform 1 is detected in all tissues except the brain and thymus, while isoform 2, isoform 3, and isoform 4 are detected at low levels in approximately half of the fetal tissues. Ref.1 Ref.3 Ref.11 Ref.13 |
| Involvement in disease | A chromosomal aberration involving SEPT9/MSF is found in therapy-related acute myeloid leukemia (t-AML). Translocation t(11;17)(q23;q25) with MLL. Ref.1 Hereditary neuralgic amyotrophy (HNA) [MIM:162100]: Autosomal dominant form of recurrent focal neuropathy characterized clinically by acute, recurrent episodes of brachial plexus neuropathy with muscle weakness and atrophy preceded by severe pain in the affected arm. HNA is triggered by environmental factors such as infection or parturition. |
| Sequence similarities | Belongs to the septin family. |
| Sequence caution | The sequence BAB14057.1 differs from that shown. Reason: Aberrant splicing. |
Ontologies
| Keywords | |
|---|---|
| Biological process | Cell cycle Cell division |
| Cellular component | Cytoplasm Cytoskeleton |
| Coding sequence diversity | Alternative splicing Chromosomal rearrangement Polymorphism |
| Disease | Disease mutation |
| Ligand | GTP-binding Nucleotide-binding |
| PTM | Phosphoprotein |
| Technical term | Complete proteome Reference proteome |
| Gene Ontology (GO) | |
| Biological_process | cell cycle Inferred from electronic annotation. Source: UniProtKB-KW cell divisionInferred from electronic annotation. Source: UniProtKB-KW protein heterooligomerizationInferred from direct assay Ref.12. Source: UniProtKB |
| Cellular_component | microtubule Inferred from direct assay Ref.12. Source: UniProtKB perinuclear region of cytoplasmInferred from direct assay Ref.12. Source: UniProtKB stress fiberInferred from direct assay Ref.12. Source: UniProtKB |
| Molecular_function | GTP binding Inferred from electronic annotation. Source: UniProtKB-KW GTPase activityTraceable author statement Ref.1. Source: ProtInc |
| Complete GO annotation... | |
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| HIF1A | Q16665 | 4 | EBI-851558,EBI-447269 | |
| SEPT14 | Q6ZU15 | 3 | EBI-851569,EBI-2009297 |
Alternative products
| This entry describes 8 isoforms produced by alternative splicing. [Align] [Select] Note: There are potentially 18 isoforms. | ||||||
| Isoform 1 (identifier: Q9UHD8-1) Also known as: Epsilon; MSF-A; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q9UHD8-2) Also known as: Alpha; The sequence of this isoform differs from the canonical sequence as follows: 1-25: MKKSYSGGTRTSSGRLRRLGDSSGP → MERDRIS | ||||||
| Isoform 3 (identifier: Q9UHD8-3) Also known as: Beta; MSF-B; The sequence of this isoform differs from the canonical sequence as follows: 1-164: Missing. | ||||||
| Isoform 4 (identifier: Q9UHD8-4) Also known as: Delta; The sequence of this isoform differs from the canonical sequence as follows: 1-251: Missing. | ||||||
| Isoform 5 (identifier: Q9UHD8-5) Also known as: Gamma; The sequence of this isoform differs from the canonical sequence as follows: 1-25: MKKSYSGGTRTSSGRLRRLGDSSGP → MSDPAVNAQLDGIISDFE | ||||||
| Isoform 7 (identifier: Q9UHD8-7) The sequence of this isoform differs from the canonical sequence as follows: 7-25: Missing. | ||||||
| Note: No experimental confirmation available. | ||||||
| Isoform 8 (identifier: Q9UHD8-8) The sequence of this isoform differs from the canonical sequence as follows: 1-112: Missing. 113-240: DISSKQVENA...VAEATPRSQE → MGSSFWEGLQ...CLATIGSDRQ | ||||||
| Note: No experimental confirmation available. | ||||||
| Isoform 9 (identifier: Q9UHD8-9) The sequence of this isoform differs from the canonical sequence as follows: 1-224: Missing. 225-240: PKPQPPVAEATPRSQE → MAGAGCTGTWSWLWGT | ||||||
| Note: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||
Molecule processing | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 586 | 586 | Septin-9 | PRO_0000173535 | |||||
Regions | |||||||||
| Nucleotide binding | 305 – 312 | 8 | GTP By similarity | ||||||
| Nucleotide binding | 445 – 453 | 9 | GTP By similarity | ||||||
Sites | |||||||||
| Binding site | 339 | 1 | GTP By similarity | ||||||
| Binding site | 365 | 1 | GTP; via amide nitrogen By similarity | ||||||
| Binding site | 501 | 1 | GTP; via amide nitrogen and carbonyl oxygen By similarity | ||||||
| Binding site | 516 | 1 | GTP By similarity | ||||||
Amino acid modifications | |||||||||
| Modified residue | 30 | 1 | Phosphoserine Ref.17 Ref.20 Ref.21 Ref.23 Ref.24 Ref.26 | ||||||
| Modified residue | 38 | 1 | Phosphothreonine Ref.21 | ||||||
| Modified residue | 42 | 1 | Phosphothreonine Ref.17 Ref.21 | ||||||
| Modified residue | 49 | 1 | Phosphothreonine By similarity | ||||||
| Modified residue | 82 | 1 | Phosphoserine Ref.24 | ||||||
| Modified residue | 85 | 1 | Phosphoserine Ref.16 Ref.24 Ref.26 | ||||||
| Modified residue | 96 | 1 | Phosphoserine Ref.24 | ||||||
| Modified residue | 142 | 1 | Phosphothreonine Ref.24 | ||||||
| Modified residue | 160 | 1 | Phosphoserine By similarity | ||||||
| Modified residue | 278 | 1 | Phosphotyrosine Ref.23 | ||||||
| Modified residue | 327 | 1 | Phosphoserine Ref.26 | ||||||
Natural variations | |||||||||
| Alternative sequence | 1 – 251 | 251 | Missing in isoform 4. | VSP_012335 | |||||
| Alternative sequence | 1 – 224 | 224 | Missing in isoform 9. | VSP_038315 | |||||
| Alternative sequence | 1 – 164 | 164 | Missing in isoform 3. | VSP_012336 | |||||
| Alternative sequence | 1 – 112 | 112 | Missing in isoform 8. | VSP_038316 | |||||
| Alternative sequence | 1 – 25 | 25 | MKKSY…DSSGP → MERDRIS in isoform 2. | VSP_012337 | |||||
| Alternative sequence | 1 – 25 | 25 | MKKSY…DSSGP → MSDPAVNAQLDGIISDFE in isoform 5. | VSP_012338 | |||||
| Alternative sequence | 7 – 25 | 19 | Missing in isoform 7. | VSP_038317 | |||||
| Alternative sequence | 113 – 240 | 128 | DISSK…PRSQE → MGSSFWEGLQVAVGLPQGCW PQGLDSGEPAEGGQLEAAPV CIVTRQSKETAGPTLGRGGW RQGSLRRGKGTSCRCRQLSP GHGPGRLTGCGECHRLPCRG LVSGFTGLRGQEEDDLAFCL ATIGSDRQ in isoform 8. | VSP_038318 | |||||
| Alternative sequence | 225 – 240 | 16 | PKPQP…PRSQE → MAGAGCTGTWSWLWGT in isoform 9. | VSP_038319 | |||||
| Natural variant | 76 | 1 | R → C. Ref.2 | VAR_020667 | |||||
| Natural variant | 106 | 1 | R → W in HNA. Ref.18 Ref.27 Ref.28 Ref.29 | VAR_033101 | |||||
| Natural variant | 111 | 1 | S → F in HNA. Ref.18 Ref.27 Ref.29 | VAR_033102 | |||||
| Natural variant | 145 | 1 | P → L. Ref.2 Ref.5 Ref.29 Corresponds to variant rs34587622 [ dbSNP | Ensembl ]. | VAR_020668 | |||||
| Natural variant | 576 | 1 | M → V. Ref.1 Ref.2 Ref.3 Ref.4 Ref.5 Ref.6 Ref.7 Ref.8 Ref.9 Ref.10 Corresponds to variant rs2627223 [ dbSNP | Ensembl ]. | VAR_020669 | |||||
Experimental info | |||||||||
| Sequence conflict | 251 | 1 | D → G in BAG64494. Ref.5 | ||||||
| Sequence conflict | 487 | 1 | V → E in BAB14057. Ref.5 | ||||||
Sequences
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25)." Osaka M., Rowley J.D., Zeleznik-Le N.J. Proc. Natl. Acad. Sci. U.S.A. 96:6428-6433(1999) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT VAL-576, TISSUE SPECIFICITY, DISEASE, CHROMOSOMAL TRANSLOCATION. |
| [2] | "Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors." Russell S.E.H., McIlhatton M.A., Burrows J.F., Donaghy P.G., Chanduloy S., Petty E.M., Kalikin L.M., Church S.W., McIlroy S., Harkin D.P., Keilty G.W., Cranston A.N., Weissenbach J., Hickey I., Johnston P.G. Cancer Res. 60:4729-4734(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3; 4 AND 5), VARIANTS CYS-76; LEU-145 AND VAL-576. |
| [3] | "Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors." Kalikin L.M., Sims H.L., Petty E.M. Genomics 63:165-172(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), VARIANT VAL-576, TISSUE SPECIFICITY, ALTERNATIVE SPLICING. |
| [4] | "Novel human cell division control protein septin D1." Zhang W., He L., Wan T., Yuan Z., Zhu X., Cao X. Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT VAL-576. |
| [5] | "Complete sequencing and characterization of 21,243 full-length human cDNAs." Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S. Sugano S.Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4; 5; 7; 8 AND 9), VARIANTS LEU-145 AND VAL-576. Tissue: Fetal brain, Mammary gland, Placenta, Teratocarcinoma, Thymus, Tongue and Trachea. |
| [6] | "Cloning of human full-length CDSs in BD Creator(TM) system donor vector." Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S., Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y., Phelan M., Farmer A. Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), VARIANT VAL-576. |
| [7] | Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., Turner R. Venter J.C.Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], VARIANT VAL-576. |
| [8] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 3), VARIANT VAL-576. Tissue: Eye and Skin. |
| [9] | "Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro." Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O. DNA Res. 6:63-70(1999) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 26-586, VARIANT VAL-576. Tissue: Brain. |
| [10] | "The full-ORF clone resource of the German cDNA consortium." Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., Wiemann S., Schupp I. BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 353-586, VARIANT VAL-576. Tissue: Testis. |
| [11] | "Genomic organization, complex splicing pattern and expression of a human septin gene on chromosome 17q25.3." McIlhatton M.A., Burrows J.F., Donaghy P.G., Chanduloy S., Johnston P.G., Russell S.E. Oncogene 20:5930-5939(2001) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY, ALTERNATIVE SPLICING. |
| [12] | "Biochemical and cell biological analyses of a mammalian septin complex, Sept7/9b/11." Nagata K., Asano T., Nozawa Y., Inagaki M. J. Biol. Chem. 279:55895-55904(2004) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH SEPT7 AND SEPT11. |
| [13] | "Expression profiling the human septin gene family." Hall P.A., Jung K., Hillan K.J., Russell S.E.H. J. Pathol. 206:269-278(2005) [PubMed] [Europe PMC] [Abstract] Cited for: TISSUE SPECIFICITY. |
| [14] | "Cytoskeletal modification of Rho guanine nucleotide exchange factor activity: identification of a Rho guanine nucleotide exchange factor as a binding partner for Sept9b, a mammalian septin." Nagata K., Inagaki M. Oncogene 24:65-76(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH ARHGEF18. |
| [15] | "Possible role of Rho/Rhotekin signaling in mammalian septin organization." Ito H., Iwamoto I., Morishita R., Nozawa Y., Narumiya S., Asano T., Nagata K. Oncogene 24:7064-7072(2005) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH RTKN. |
| [16] | "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks." Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M. Cell 127:635-648(2006) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [17] | "A probability-based approach for high-throughput protein phosphorylation analysis and site localization." Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P. Nat. Biotechnol. 24:1285-1292(2006) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30 AND THR-42, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [18] | "SEPT9 sequence alternations causing hereditary neuralgic amyotrophy are associated with altered interactions with SEPT4/SEPT11 and resistance to Rho/Rhotekin-signaling." Sudo K., Ito H., Iwamoto I., Morishita R., Asano T., Nagata K. Hum. Mutat. 28:1005-1013(2007) [PubMed] [Europe PMC] [Abstract] Cited for: SUBCELLULAR LOCATION, INTERACTION WITH SEPT4, VARIANTS HNA TRP-106 AND PHE-111. |
| [19] | "Characterization of a SEPT9 interacting protein, SEPT14, a novel testis-specific septin." Peterson E.A., Kalikin L.M., Steels J.D., Estey M.P., Trimble W.S., Petty E.M. Mamm. Genome 18:796-807(2007) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH SEPT14, SUBCELLULAR LOCATION. |
| [20] | "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis." Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III J. Proteome Res. 7:1346-1351(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [21] | "A quantitative atlas of mitotic phosphorylation." Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., Elledge S.J., Gygi S.P. Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; THR-38 AND THR-42, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [22] | "Septins regulate bacterial entry into host cells." Mostowy S., Nam Tham T., Danckaert A., Guadagnini S., Boisson-Dupuis S., Pizarro-Cerda J., Cossart P. PLoS ONE 4:E4196-E4196(2009) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH SEPT2; SEPT6; SEPT7 AND SEPT11, ASSOCIATION WITH ACTIN FILAMENTS AND MICROTUBULES. |
| [23] | "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions." Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., Rodionov V., Han D.K. Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30 AND TYR-278, MASS SPECTROMETRY. Tissue: Leukemic T-cell. |
| [24] | "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis." Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M. Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; SER-82; SER-85; SER-96 AND THR-142, MASS SPECTROMETRY. Tissue: Cervix carcinoma. |
| [25] | "Initial characterization of the human central proteome." Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J. BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. |
| [26] | "System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation." Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B. Sci. Signal. 4:RS3-RS3(2011) [PubMed] [Europe PMC] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-30; SER-85 AND SER-327, MASS SPECTROMETRY. |
| [27] | "Mutations in SEPT9 cause hereditary neuralgic amyotrophy." Kuhlenbaeumer G., Hannibal M.C., Nelis E., Schirmacher A., Verpoorten N., Meuleman J., Watts G.D.J., De Vriendt E., Young P., Stoegbauer F., Halfter H., Irobi J., Goossens D., Del-Favero J., Betz B.G., Hor H., Kurlemann G., Bird T.D. Chance P.F.Nat. Genet. 37:1044-1046(2005) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS HNA TRP-106 AND PHE-111. |
| [28] | "Dysmorphic syndrome of hereditary neuralgic amyotrophy associated with a SEPT9 gene mutation -- a family study." Laccone F., Hannibal M.C., Neesen J., Grisold W., Chance P.F., Rehder H. Clin. Genet. 74:279-283(2008) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT HNA TRP-106. |
| [29] | "SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy." Hannibal M.C., Ruzzo E.K., Miller L.R., Betz B., Buchan J.G., Knutzen D.M., Barnett K., Landsverk M.L., Brice A., LeGuern E., Bedford H.M., Worrall B.B., Lovitt S., Appel S.H., Andermann E., Bird T.D., Chance P.F. Neurology 72:1755-1759(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANTS HNA TRP-106 AND PHE-111, VARIANT LEU-145. |
| + | Additional computationally mapped references. |
Cross-references
Entry information
| Entry name | SEPT9_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q9UHD8 Secondary accession number(s): A8K2V3 Q9Y5W4 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 17 Human chromosome 17: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| SIMILARITY comments Index of protein domains and families |

Clusters with
